key: cord-0764676-gqzbonzp
authors: Rao, Shivani; Warrior, Surbhi; Luo, Shengyuan; Gezer, Sefer; Venugopal, Parameswaran; Jain, Shivi
title: Impact of blood type on thrombosis and disease severity in adult COVID-19 patients()
date: 2021-08-26
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.08.024
sha: 692b7f459062b2b0d53889a64ec7b8a132d2c289
doc_id: 764676
cord_uid: gqzbonzp

nan

SARS-CoV-2, which causes COVID-19, is a novel virus characterized by its unknown origin and rapid spread of disease. The virus has infected more than 211 million individuals worldwide and its associated disease has caused over 4,430,000 deaths, as of August 22, 2021 [1] .

A preliminary study conducted in New York discovered a relationship between blood type and susceptibility to as well as severity of COVID-19 [2] . Blood type A was associated with higher severity of disease and blood type O corresponded with a lower risk of infection and severe disease.

The hallmark of severe COVID-19 is thromboembolic complications, among other symptoms. The endothelial proliferation of SARS-CoV-2 and its resultant damage to the vascular system can activate the coagulation cascade and result in thrombosis. In addition, the immobility of severe and critical patients in ICUs increases their likelihood of developing thrombosis. A study conducted in early 2020 determined that individuals with non-O blood types were at an increased risk for certain thromboembolic events [3] . In addition, blood type O patients typically have lower plasma levels of von Willebrand factor (VWF) [4] . Lower levels of von Willebrand proteins in vascular endothelium have been shown to decrease clotting performance and thus reduce risk for thrombosis. Furthermore, blood type O is thought to protect against vascular complications in malaria [5] . This study was conducted to test whether different blood types in COVID-19 patients are correlated with variable protection against thrombosis.

Throughout this analysis of data, all patients who had at least one positive PCR result indicating the presence of SARS-CoV-2 were considered COVID-19 positive (+). The type and screen (T&S) method was used to determine ABO blood group and Rh type. The present study originally included 1264 COVID-19+ patients hospitalized between March 1, 2020, and June 26, 

This study found no increased prevalence of one blood type over another between COVID-19+ patients with thrombosis compared to COVID-19+ patients without thrombosis, implying that patients are not at higher risk for thrombosis in general from COVID-19 infection based on blood type. When further stratifying by Rh factor, there was also no difference in prevalence of thrombosis based on blood types, suggesting that Rh type does not modify the association between blood type and COVID-19 associated thrombosis in general. However, blood type A+ individuals were at an increased risk of developing PE, a specific thrombotic event, as compared to blood type O+, respectively, even after controlling for confounding variables.

While the findings regarding PE suggest that A+ blood type may predispose a patient to certain COVID-19 associated thromboembolic events, this study was limited by its retrospective nature and its setting within a single medical center. Small sample size may have caused a Type II error to occur. Furthermore, severity of disease may have also skewed blood typing data, as patients who were less severely affected by COVID-19 were unlikely to require blood transfusion and hence blood typing. It is also known that individuals with blood type O generally have decreased levels of VWF. Thus, investigating the relationship between VWF level and severity of COVID-19 through prospective studies may bring more insight into COVID-19 associated coagulopathy.

J o u r n a l P r e -p r o o f Journal Pre-proof

Johns Hopkins Coronavirus Resource Center

Associations between blood type and COVID-19 infection, intubation, and death

Genetically Determined ABO Blood Group and its Associations With Health and Disease

ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

The ABO blood group system and Plasmodium falciparum malaria

I would like to offer my special thanks to Perumal Thiagarajan, Robert Taylor, Jan Macfarland, and Ajit Divgi for offering their personal advice on the study and providing editorial assistance.All research was conducted through RUMC. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.J o u r n a l P r e -p r o o f Journal Pre-proof